mTOR
MTOR (mechanistic target of rapamycin) is a serine/threonine kinase that regulates cellular metabolism, growth ad survival. It mediates the cellular response to stress, growth factor and hormone etc. It is involved in cancer, aging and neurodegenerative diseases etc.
Products for mTOR
- Cat.No. Product Name Information
- GC17330 (+)-Usniacin (+)-Usniacin is isolated from isolated from lichens, binds at the ATP-binding pocket of mTOR, and inhibits mTORC1/2 activity. (+)-Usniacin inhibits the phosphorylation of mTOR downstream effectors: Akt (Ser473), 4EBP1, S6K, induces autophay, with anti-cancer activity. (+)-Usniacin possesses antimicrobial activity against a number of planktonic gram-positive bacteria, including Staphylococcus aureus, Enterococcus faecalis, and Enterococcus faecium.
- GC63524 (32-Carbonyl)-RMC-5552 (32-Carbonyl)-RMC-5552 is a potent mTOR inhibitor. (32-Carbonyl)-RMC-5552 inhibits mTORC1 and mTORC2 substrate (p-P70S6K-(T389), p-4E-BP1-(T37/36), AND p-AKT1/2/3-(S473)) phosphorylation with pIC50s of > 9, >9 and between 8 and 9, respectively (patent WO2019212990A1, example 2).
- GC32767 3BDO A butyrolactone derivative and autophagy inhibitor
- GC35395 Arnicolide D Arnicolide D is a sesquiterpene lactone isolated from Centipeda minima. Arnicolide D modulates the cell cycle, activates the caspase signaling pathway and inhibits the PI3K/AKT/mTOR and STAT3 signaling pathways. Arnicolide D inhibits Nasopharyngeal carcinoma (NPC) cell viability in a concentration- and time-dependent manner.
- GC13029 AZD2014 AZD2014 (AZD2014) is an ATP competitive mTOR inhibitor with an IC50 of 2.81 nM. AZD2014 inhibits both mTORC1 and mTORC2 complexes.
- GC16380 AZD8055 MTOR inhibitor
- GC13271 BEZ235 Tosylate
- GC35509 BGT226 BGT226 (NVP-BGT226) is a PI3K (with IC50s of 4 nM, 63 nM and 38 nM for PI3Kα, PI3Kβ and PI3Kγ)/mTOR dual inhibitor which displays potent growth-inhibitory activity against human head and neck cancer cells.
- GC30229 Cbz-B3A Cbz-B3A is a potent and selective inhibitor of mTORC1 signaling that appear to bind to ubiquilins 1, 2, and 4, and Cbz-B3A inhibits the phosphorylation of eIF4E-binding protein 1 (4EBP1).
- GC16654 CC-115 mTOR/DNA-PK inhibitor
- GC34121 CC-115 hydrochloride CC-115 hydrochloride is a potent and dual DNA-PK and mTOR kinase inhibitor with IC50s of 13 nM and 21 nM, respectively. CC-115 blocks both mTORC1 and mTORC2 signaling.
- GC13648 CC-223 CC-223 (CC-223) is a potent, selective, and orally bioavailable inhibitor of mTOR kinase, with an IC50 value for mTOR kinase of 16 nM. CC-223 inhibits both mTORC1 and mTORC2.
- GC65944 CC214-2 CC214-2 is a potent and dual inhibitor of mTORC1/mTORC2. Mycobacterium tuberculosis modulates mammalian target of rapamycin (mTOR) signaling to impede autophagy. CC214-2 has the potential to shorten the duration of TB.
- GC38419 Cyclovirobuxine D An alkaloid with diverse biological activities
- GC19114 CZ415 CZ415 is a potent and highly selective mTOR inhibitor with a pIC50 of 8.07.
- GC18583 D-α-Hydroxyglutaric Acid Over-produced in the human neurometabolic disease D-2-HGA
- GN10583 Dihydromyricetin
- GC62495 DS-7423 DS-7423 is a dual PI3K and mTOR inhibitor, with IC50 values of 15.6 nM, 34.9 nM for PI3Kα and mTOR, respectively. DS-7423 possesses anti-tumor activity.
- GC43585 eCF309 eCF309 is an ATP-competitive inhibitor of mTOR (IC50 = 15 nM in vitro and in cells) with >65-fold selectivity over other kinases, including PI3Ks.
- GC10196 ETP-46464 ATR inhibitor,potent and selective
- GC13601 Everolimus (RAD001) A rapamycin derivative
- GC33355 FT-1518 FT-1518 is a new generation selective, potent and oral bioavailable mTORC1 and mTORC2 inhibitor, and exhibits antitumor activity.
- GC10228 GDC-0084 PI3K and mTOR inhibitor, brain-permeable
- GC12021 GDC-0349 MTOR inhibitor
- GC11177 GDC-0980 (RG7422) GDC-0980 (RG7422) (GDC-0980; GNE 390; RG 7422) is a selective, potent, orally bioavailable Class I PI3 kinase and mTOR kinase (TORC1/2) inhibitor with IC50s of 5 nM/27 nM/7 nM/14 nM for PI3Kα/PI3Kβ/PI3Kδ/PI3Kγ, and with aKiof 17 nM for mTOR.
- GC10900 GDC-mTOR inhibitor
- GC17338 GNE-317 potent, brain-penetrant PI3K inhibitor
- GC10340 GNE-477 dual PI3K/mTOR inhibitor
- GC15423 GNE-493 Pan-PI3K/mTOR inhibitor
- GC11018 GSK1059615 PI3K and mTOR inhibitor,potent and reversible
- GC15072 GSK2126458 GSK2126458 (GSK2126458) is an orally active and highly selective inhibitor of PI3K with Kis of 0.019 nM/0.13 nM/0.024 nM/0.06 nM and 0.18 nM/0.3 nM for p110α/β/δ/γ, mTORC1/2, respectively. GSK2126458 has anti-cancer activity.
- GA10282 H-Leu-OH
- GC65460 HDACs/mTOR Inhibitor 1 HDACs/mTOR Inhibitor 1 is a dual Histone Deacetylases (HDACs) and mammalian target of Rapamycin (mTOR) target inhibitor for treating hematologic malignancies, with IC50s of 0.19 nM, 1.8 nM, 1.2 nM and >500 nM for HDAC1, HDAC6, mTOR and PI3Kα, respectively. HDACs/mTOR Inhibitor 1 stimulates cell cycle arrest in G0/G1 phase and induce tumor cell apoptosis with low toxicity in vivo.
- GC38088 Hederacolchiside A1
- GC62572 hSMG-1 inhibitor 11e hSMG-1 inhibitor 11e is a potent and selective hSMG-1 kinase inhibitor with an IC50 of 900-fold selectivity over mTOR (IC50 of 45 nM), PI3Kα/γ (IC50s of 61 nM and 92 nM) and CDK1/CDK2 (IC50s of 32 μM and 7.1 μM).
- GC61925 hSMG-1 inhibitor 11j hSMG-1 inhibitor 11j, a pyrimidine derivative, is a potent and selective inhibitor of hSMG-1, with an IC50 of 0.11 nM. hSMG-1 inhibitor 11j exhibits >455-fold selectivity for hSMG-1 over mTOR (IC50=50 nM), PI3Kα/γ (IC50=92/60 nM) and CDK1/CDK2 (IC50=32/7.1 μM). hSMG-1 inhibitor 11j can be used for the research of cancer.
- GC10969 INK 128(MLN0128) INK 128 (MLN0128) (INK-128; MLN0128; TAK-228) is an orally available, ATP-dependent mTOR1/2 inhibitor with an IC50 of 1 nM for mTOR kinase.
- GC34909 JR-AB2-011 A selective mTORC2 inhibitor
- GC14346 KU-0060648 Dual DNA-PK/PI3-K inhibitor, ATP-competitive
- GC15167 KU-0063794 MTORC1 and mTORC2 inhibitor
- GC68037 L-Leucine-1-13C,15N
- GC68219 L-Leucine-13C
- GC63833 L-Leucine-15N
- GC66357 L-Leucine-d2 L-Leucine-d2 is the deuterium labeled L-Leucine. L-Leucine is an essential branched-chain amino acid (BCAA), which activates the mTOR signaling pathway.
- GC64188 L-Leucine-d3 L-Leucine-d3 is the deuterium labeled L-Leucine.
- GC12045 LY 303511 An inhibitor of cell proliferation
- GC14371 LY3023414 LY3023414 (LY3023414) potently and selectively inhibits class I PI3K isoforms, DNA-PK, and mTORC1/2 with IC50s of 6.07 nM, 77.6 nM, 38 nM, 23.8 nM, 4.24 nM and 165 nM for PI3Kα, PI3Kβ, PI3Kδ, PI3Kγ, DNA-PK and mTOR, respectively. LY3023414 potently inhibits mTORC1/2 at low nanomolar concentrations.
- GC64402 MHY-1685 MHY-1685, a novel mammalian target of rapamycin (mTOR) inhibitor, provides opportunities to improve hCSC-based myocardial regeneration.
-
GC13790
MHY1485
MHY1485 is a potent activator of mTOR, which inhibits autophagy and the fusion between autophagosomes and lysosomes.
- GC65143 MKC-1 MKC-1 (Ro-31-7453) is an orally active and potent cell cycle inhibitor with broad antitumor activity. MKC-1 inhibits the Akt/mTOR pathway. MKC-1 arrests cellular mitosis and induces cell apoptosis by binding to a number of different cellular proteins including tubulin and members of the importin β family.
- GC60258 MT 63-78 MT 63-78 is a specific and potent direct AMPK activator with an EC50 of 25 μM. MT 63–78 also induces cell mitotic arrest and apoptosis. MT 63-78 blocks prostate cancer growth by inhibiting the lipogenesis and mTORC1 pathways. MT 63-78 has antitumor effects.
- GC64304 MTI-31 MTI-31 is a potent, orally active and highly selective inhibitor of mTORC1 and mTORC2.
- GC65115 mTOR inhibitor-1 mTOR inhibitor-1 is a novel mTOR pathway inhibitor which can suppress cells proliferation and inducing autophagy.
- GC62339 mTOR inhibitor-8 mTOR inhibitor-8 is an mTOR inhibitor and autophagy inducer. mTOR inhibitor-8 inhibits the activity of mTOR via FKBP12 and induces autophagy of A549 human lung cancer cells.
- GC18089 Nordihydroguaiaretic acid A non-selective LO inhibitor
- GC33014 NSC781406 A dual inhibitor of PI3K and mTOR
- GC63121 NV-5138 NV-5138, a leucine analog, is the first selective and orally active brain mTORC1 activator, binding to Sestrin2.
- GC63122 NV-5138 hydrochloride NV-5138 hydrochloride, a leucine analog, is the first selective and orally active brain mTORC1 activator, binding to Sestrin2.
- GC16145 NVP-BGT226 BGT226 (NVP-NVP-BGT226) is a PI3K (with IC50s of 4 nM, 63 nM and 38 nM for PI3Kα, PI3Kβ and PI3Kγ) /mTOR dual inhibitor which displays potent growth-inhibitory activity against human head and neck cancer cells.
- GC14071 OSI-027 MTORC1/ mTORC2 inhibitor
- GC15740 OXA-01 mTORC1 and mTORC2 inhibitor
-
GC12773
Palomid 529
PI3K/Akt/mTOR inhibitor
- GC16417 PF-04691502 PI3K/mTOR (FRAP) inhibitor
- GC19283 PF-04979064 PF-04979064 is a potent and selective PI3K/mTOR dual kinase inhibitor with Kis of 0.13 nM and 1.42 nM for PI3Kα and mTOR, respectively.
- GC15653 PF-05212384 (PKI-587) PF-05212384 (PKI-587) (PKI-587) is a highly potent dual inhibitor of PI3Kα, PI3Kγ, and mTOR with IC50s of 0.4 nM, 5.4 nM and 1.6 nM, respectively. PF-05212384 (PKI-587) is equally effective in both complexes of mTOR, mTORC1 and mTORC2.
- GC11165 PI-103 Class I PI3K, mTOR and DNA-PK inhibitor
- GC16379 PI-103 Hydrochloride A potent, cell-permeable PI3K inhibitor
- GC36909 PI3Kα/mTOR-IN-1 PI3Kα/mTOR-IN-1 is a potent PI3Kα/mTOR dual inhibitor, with an IC50 of 7 nM for PI3Kα in a cell assay, and Kis of 10.6 nM and 12.5 nM for mTOR and PI3Kα in a cell free assay , respectively.
- GC62140 PKI-179 PKI-179 is a potent and orally active dual PI3K/mTOR inhibitor, with IC50s of 8 nM, 24 nM, 74 nM, 77 nM, and 0.42 nM for PI3K-α, PI3K-β, PI3K-γ, PI3K-δ and mTOR, respectively. PKI-179 also exhibits activity over E545K and H1047R, with IC50s of 14 nM and 11 nM, respectively. PKI-179 shows anti-tumor activity in vivo.
-
GC17104
PKI-402
PI3K inhibitor,selective, reversible and ATP-competitive
- GN10709 Polyphyllin A
- GC33115 Pomiferin (NSC 5113) Pomiferin (NSC 5113) (NSC 5113) acts as an potential inhibitor of HDAC, with an IC50 of 1.05 μM, and also potently inhibits mTOR (IC50, 6.2 μM).
- GC11003 PP121 Dual inhibitor of tyrosine and phosphoinositide kinases
- GC15904 PP242 PP242 (PP 242) is a selective and ATP-competitive mTOR inhibitor with an IC50 of 8 nM. PP242 inhibits both mTORC1 and mTORC2 with IC50s of 30 nM and 58 nM, respectively.
- GC33385 PQR-530 A dual inhibitor of PI3Kα and mTOR
- GC19300 PQR309 PQR309 (PQR309) is a potent, brain-penetrant, orally bioavailable, pan-class I PI3K/mTOR inhibitor with IC50s of 33 nM, 451 nM, 661 nM, 708 nM and 89 nM for PI3Kα, PI3Kδ, PI3Kβ, PI3Kγ and mTOR, respectively. PQR309 is an mTORC1 and mTORC2 inhibitor.
- GC32891 PQR620 PQR620 is an orally bioavailable and selective brain penetrant inhibitor of mTORC1/2.
- GC18032 QL-IX-55
- GC11607 Rapalink-1 third-generation mTOR inhibitor
-
GC15031
Rapamycin (Sirolimus)
An allosteric inhibitor of mTORC1
- GC48027 Rapamycin-d3 An internal standard for the quantification of rapamycin
- GC39292 Rheb inhibitor NR1 Rheb inhibitor NR1 is a Rheb inhibitor with an IC50 of 2.1??M in the Rheb-IVK assay.
- GC13071 Ridaforolimus (Deforolimus, MK-8669) Ridaforolimus (Deforolimus, MK-8669) (MK-8669) is a potent and selective mTOR inhibitor; inhibits ribosomal protein S6 phosphorylation with an IC50 of 0.2 nM in HT-1080 cells.
- GC62649 RMC-5552 RMC-5552 is a potent and selective inhibitor of mTORC1. RMC-5552 inhibits phosphorylation of mTORC1 pS6K and p4EBP1 with IC50s of 0.14 nM and 0.48 nM, respectively. RMC-5552 has anti-cancer activity.
- GC63894 RMC-6272 RMC-6272 (RM-006) is a bi-steric mTORC1-selective inhibitor. RMC-6272 exhibits potent and selective (> 10-fold) inhibition of mTORC1 over mTORC2. RMC-6272 shows improved inhibition of mTORC1 in comparison to Rapamycin, and induces more cell death in TSC2 null tumors.
- GC38609 Rotundic acid Rotundic acid, a triterpenoid obtained from I.
- GC64278 RP-3500 RP-3500 (ATR inhibitor 4) is an orally active, selective ATR kinase inhibitor (ATRi) with an IC50 of 1.00 nM in biochemical assays. RP-3500 shows 30-fold selectivity for ATR over mTOR (IC50=120 nM) and >2,000-fold selectivity over ATM, DNA-PK, and PI3Kα kinases. RP-3500 has potent antitumor activity.
- GN10127 Salidroside Salidroside is a glycoside with multiple biological activities and has pharmacological effects such as anti-cancer, antioxidant, anti-aging, anti-diabetic, anti-diabetic, anti-hypertensive, anti-inflammatory, and immune regulation.
-
GC12573
Temsirolimus
A MTOR inhibitor
- GC61336 TMBIM6 antagonist-1 TMBIM6 antagonist-1, a potential TMBIM6 antagonist, prevents TMBIM6 binding to mTORC2, decreases mTORC2 activity, and also regulates TMBIM6-leaky Ca2+.
-
GC10131
Torin 1
MTOR inhibitor,potent and selective
- GC13858 Torin 2 MTOR inhibitor,highly potent and selective
- GC37922 Voxtalisib A dual inhibitor of PI3K and mTORC
- GC17771 VS-5584 (SB2343) A selective PI3K/mTOR kinase inhibitor
- GC10583 WAY-600 MTOR inhibitor
- GC14675 WYE-125132 (WYE-132) WYE-125132 (WYE-132) (WYE-125132) is a highly potent, ATP-competitive, and specific mTOR kinase inhibitor (IC50: 0.19±0.07 nM; >5,000-fold selective versus PI3Ks). WYE-125132 (WYE-132) (WYE-125132) inhibits mTORC1 and mTORC2.
- GC13321 WYE-687 MTOR inhibitor,ATP-competitive and selective
- GC38473 WYE-687 dihydrochloride WYE-687 dihydrochloride is an ATP-competitive mTOR inhibitor with an IC50 of 7 nM. WYE-687 dihydrochloride concurrently inhibits activation of mTORC1 and mTORC2. WYE-687 also inhibits PI3Kα and PI3Kγ with IC50s of 81 nM and 3.11 μM, respectively.
- GC16481 XL388 An mTOR inhibitor